Home/Filings/4/0001415889-25-006684
4//SEC Filing

Winningham Rick E 4

Accession 0001415889-25-006684

CIK 0001583107other

Filed

Mar 3, 7:00 PM ET

Accepted

Mar 4, 6:17 PM ET

Size

6.4 KB

Accession

0001415889-25-006684

Insider Transaction Report

Form 4
Period: 2025-02-28
Winningham Rick E
DirectorChief Executive Officer
Transactions
  • Award

    Ordinary Shares

    2025-02-28$9.35/sh+2,178$20,3641,778,144 total
Holdings
  • Ordinary Shares

    (indirect: As Custodian)
    3,900
  • Ordinary Shares

    (indirect: By Trust)
    92,567
Footnotes (1)
  • [F1]Reflects an acquisition from the Issuer pursuant to a restricted share purchase agreement under the Issuer's Amended and Restated 2013 Equity Incentive Plan at a per-share price equal to the closing per-share price of the Issuer's ordinary shares on the Nasdaq Global Market on February 28, 2025.

Issuer

Theravance Biopharma, Inc.

CIK 0001583107

Entity typeother

Related Parties

1
  • filerCIK 0001302443

Filing Metadata

Form type
4
Filed
Mar 3, 7:00 PM ET
Accepted
Mar 4, 6:17 PM ET
Size
6.4 KB